Drug intelligence / Profile preview

H2-TAT peptides

Development stage
Preclinical
Modality
Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration
Intravenous, Intratumoral, Intracerebroventricular
01

Overview

H2-TAT peptides are synthetic chimeric cell-penetrating peptides that combine the HIV trans-activator of transcription (TAT) protein transduction domain with a pH-responsive hemagglutinin 2 (HA2) domain from influenza A virus. The TAT domain is rich in arginine and lysine residues and facilitates efficient cellular entry by interacting with cell membranes through electrostatic interactions. The HA2 segment enables endosomal escape via pH-dependent membrane fusion activity. Together, these domains synergistically enhance intracellular delivery of various cargoes such as siRNA or drugs by promoting both cellular uptake and endosomal release. H2-TAT peptides have been studied primarily as nonviral vectors for gene silencing applications and drug delivery systems in cancer research. They protect nucleic acids from degradation and improve cytoplasmic delivery efficiency without significant toxicity[1]. Their performance depends on the mode of attachment to cargoes (e.g., multicomponent complexes or conjugates), which affects their surface configuration and biological activity[1].

Other names
TAT-HA2 peptideTAT-HA-2 peptideTAT-HA 2 peptideHA2-TAT peptideHA-2-TAT peptideHA 2-TAT peptide
02

Targets

Cellular and endosomal lipid bilayer

Beyond the preview

Go deeper on H2-TAT peptides.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on H2-TAT peptides.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call